BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Endometriosis and women's health clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for endometriosis: 33 (27 sponsors; 4 newly posted in the last 180 days, 0 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 12.1, rank 59 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 1, Phase 2 4, Phase 3 4, Phase 4 1, N/A 23.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Sumitomo Pharma Switzerland GmbH3NA 2, P3 101
AbbVie ABBV1P3 100
Hope Medicine (Nanjing) Co., Ltd1P3 100
Kissei Pharmaceutical Co., Ltd.1P3 100
ZIWIG3NA 301
EDAP TMS S.A. FOCL2NA 200
Samphire Group, Inc.2NA 211
Abbott ABT1NA 100
Aesculap AG1NA 101
Antev Ltd. new entrant1P2 110
Arafarma Group, S.A.1NA 100
Aspira Women's Health AWHL1NA 101
Bio Meds Pharmaceutica Ltda1P4 101
Changchun GeneScience Pharmaceutical Co., Ltd.1P2 100
Cycle Therapeutics Ltd1NA 100
Diamens FlexCo1NA 100
Erbe Elektromedizin GmbH1NA 100
Gesynta Pharma AB1P2 100
Hera Biotech, Inc.1P2 100
Hyivy Health Inc1NA 101
Lyv Healthcare1NA 100
Medtronic - MITG MDT1NA 100
Monath Electronic1NA 100
Pearsanta, Inc1NA 100
SWIMS America Corp. new entrant1NA 111

New-entrant sponsors: Antev Ltd., SWIMS America Corp..

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Angitia BiopharmaceuticalsNCT06577935 A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)Postmenopausal Osteoporosisactive not recruiting379
2027-01 est.P3Qilu Pharmaceutical Co., Ltd.NCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Postmenopausal Women With Osteoporosis at High Risk of Fracturerecruiting278
2027-01-03 est.P2Shenzhen Kangzhe Biotechnology Co., Ltd.NCT07402369 Phase II Study of CMS-D002 Capsule for Uterine Fibroids With MenorrhagiaUterine Fibroids With Menorrhagiarecruiting120
2027-02 est.P1/P2AbCellera Biologics Inc. ABCLNCT07118891 Study Evaluating ABCL635 for Vasomotor Symptoms of MenopauseVasomotor Symptoms Associated With Menopause; Healthy Volunteersactive not recruiting136

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT06671548 Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsHeavy Menstrual Bleeding; Uterine Fibroidsrecruiting120
2026-07-30 est.P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07579936 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPostmenopausal Women With Osteoporosisrecruiting200
2026-06-01 est.P2/P3Jiangsu HengRui Medicine Co., Ltd.NCT05442827 A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine FibroidsUterine Fibroids With Menorrhagiaunknown357

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "endometriosis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.